The world's largest beauty company just mapped where the growth is, and it is not where it used to be. Per L'Oréal's 2025 annual results, published on 12 February 2026, full-year sales reached €44.05 billion, up 4.0% like-for-like, while fourth-quarter sales of €11.3 billion rose 6% like-for-like but missed forecasts of around 7% on weakness in Asia, per Reuters' coverage of 12 February 2026. North America, by contrast, beat expectations.
Figures here come from the company's results release and Reuters' reporting; they describe sales performance, not how any product performs on skin.
Which regions grew, and which did not?
North America outperformed, Asia undershot, and the divergence moved markets: Reuters reported on 13 February 2026 that the Asia shortfall pressured L'Oréal's shares, with the stock seen falling 5-7% after the slight miss. The company still described the year as outperformance in an improving beauty market, and growth came in across divisions and regions overall, per the results release. The pattern is the story: the Chinese beauty boom that powered the last decade of prestige growth is no longer the engine, while American demand carried the quarter.
What does a 74.3% gross margin mean for shoppers?
It signals pricing power held. L'Oréal's gross margin rose 10 basis points to 74.3% for 2025, per the annual results, meaning the company converted more of each sales euro after production costs. For consumers, that usually reads as a brand portfolio that maintained prices and premium mix rather than discounting through a soft patch, particularly in haircare and fragrance-driven categories.
Why should label readers track a sales report?
Because where the money goes decides what gets formulated next. Sales momentum in North America tends to pull research and launch budgets toward the ingredient stories that region responds to: clinical actives, dermatologist positioning, and science-backed claims. Asia's slowdown, meanwhile, has historically pushed brands to fight harder on whitening-adjacent and premium skincare innovation there, per the company's own regional commentary over recent years.
The 12 February release is also a timing marker for what comes next. L'Oréal enters 2026 with the Kering Beauté acquisition signed in October 2025 and Medik8 in its portfolio, per the company's announcements, meaning the growth map drawn in these results will soon include new luxury fragrance and clinical skincare lines competing for the same American shelf space the quarter just proved is willing to spend.
For more context, read Coty Hands Gucci Beauty Back a Year Early, and L'Oréal Steps In.
For more context, read estee lauder fiscal 2026 results.
For more context, read p&g thorne acquisition.